Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of DNL104 in healthy volunteers
NL-OMON27833Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD) comparing DNL104 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events and serious adverse events, Concomitant medication use and 10 more. Started Jan 2017; status: completed.
02
Drugs
DNL104
03
Conditions
amyotrophic lateral sclerosis (ALS)Alzheimer's disease (AD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON27833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27833.